{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-23-007388","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2023-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.207387+00:00","generated_at":"2026-06-09T06:06:44.869727+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"InMed Pharmaceuticals raises $5.2M through private placement and option exercise","bullets":["Gross proceeds ~$5.2M from sale of 3,012,049 pre-funded warrants and options; existing holders exercised 3,272,733 options at $0.83.","Issued new preferred investment options to purchase up to 6,545,466 shares at $0.83, exercisable immediately, expire in 5.5 years.","H.C. Wainwright acted as exclusive placement agent; received 7.5% cash fee and warrants for 408,511 shares at $1.0375.","Proceeds to fund pipeline development, BayMedica commercial sales, and general working capital.","Securities unregistered; company to file resale registration statement within 50-80 days of closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-23-007388","json":"https://secwatch.observer/filing/0001013762-23-007388.json","markdown":"https://secwatch.observer/filing/0001013762-23-007388.md","text":"https://secwatch.observer/filing/0001013762-23-007388.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000101376223007388/0001013762-23-007388-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000101376223007388/ea187408-8k_inmedpharm.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T06:06:44.869727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1053c18096545b115b1975680a1809b2fd54e0e9","claim":"InMed Pharmaceuticals Inc. entered into Purchase Agreement with two institutional accredited investors.","evidence_excerpt":"On October 24, InMed Pharmaceuticals Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with two institutional accredited investors (the “Purchasers”), for the sale and issuance of an aggregate of 3,012,049 of its common shares (or pre-funded warrants in lieu thereof) at a purchase price of $0.83 per share (or pre-funded warrant in lieu thereof).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000101376223007388/0001013762-23-007388-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"two institutional accredited investors"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}